BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25006841)

  • 21. Pulmonary neuroendocrine tumors: an entity in search of cytologic criteria.
    Huang CC; Collins BT; Flint A; Michael CW
    Diagn Cytopathol; 2013 Aug; 41(8):689-96. PubMed ID: 23166111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine tumors of the lung: clinicopathological and molecular features.
    Iyoda A; Azuma Y; Sano A
    Surg Today; 2020 Dec; 50(12):1578-1584. PubMed ID: 32193632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
    Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
    Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuroendocrine tumors of the lung].
    Takei H; Asamura H
    Nihon Rinsho; 2004 May; 62(5):877-82. PubMed ID: 15148812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biology and novel therapeutics for neuroendocrine tumors of the lung.
    Jafri N; Salgia R
    J Biol Regul Homeost Agents; 2004; 18(3-4):275-90. PubMed ID: 15786694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
    Pelosi G; Fabbri A; Cossa M; Sonzogni A; Valeri B; Righi L; Papotti M
    Semin Diagn Pathol; 2015 Nov; 32(6):469-79. PubMed ID: 26561395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and management of typical and atypical lung carcinoids.
    Pusceddu S; Lo Russo G; Macerelli M; Proto C; Vitali M; Signorelli D; Ganzinelli M; Scanagatta P; Duranti L; Trama A; Buzzoni R; Pelosi G; Pastorino U; de Braud F; Garassino MC
    Crit Rev Oncol Hematol; 2016 Apr; 100():167-76. PubMed ID: 26917456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
    Caplin ME; Baudin E; Ferolla P; Filosso P; Garcia-Yuste M; Lim E; Oberg K; Pelosi G; Perren A; Rossi RE; Travis WD;
    Ann Oncol; 2015 Aug; 26(8):1604-20. PubMed ID: 25646366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Typical and Atypical Carcinoids of the Lung: a Surgical Treatment Strategy].
    Kaifi JT; Schmid S; Passlick B
    Zentralbl Chir; 2016 Feb; 141(1):105-20. PubMed ID: 26902582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
    Travis WD
    Thorac Surg Clin; 2014 Aug; 24(3):257-66. PubMed ID: 25065926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Iijima H; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Pathol Res Pract; 2008; 204(8):553-61. PubMed ID: 18440724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.
    Kaemmerer D; Specht E; Sänger J; Wirtz RM; Sayeg M; Schulz S; Lupp A
    J Clin Endocrinol Metab; 2015 Mar; 100(3):831-40. PubMed ID: 25494861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrum of pulmonary neuroendocrine proliferations and neoplasms.
    Benson RE; Rosado-de-Christenson ML; Martínez-Jiménez S; Kunin JR; Pettavel PP
    Radiographics; 2013 Oct; 33(6):1631-49. PubMed ID: 24108555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary neuroendocrine/carcinoid tumors: a review article.
    Bertino EM; Confer PD; Colonna JE; Ross P; Otterson GA
    Cancer; 2009 Oct; 115(19):4434-41. PubMed ID: 19562772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
    Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
    Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine neoplasms of the larynx: an overview.
    Ferlito A; Silver CE; Bradford CR; Rinaldo A
    Head Neck; 2009 Dec; 31(12):1634-46. PubMed ID: 19536850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neuroendocrine tumors of the lung].
    Oliaro A; Donati G; Filosso PL; Ruffini E
    Minerva Chir; 2000; 55(1-2):7-16. PubMed ID: 10832278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
    Wolin EM
    Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative proteomics of pulmonary tumors with neuroendocrine differentiation.
    Cho NH; Koh ES; Lee DW; Kim H; Choi YP; Cho SH; Kim DS
    J Proteome Res; 2006 Mar; 5(3):643-50. PubMed ID: 16512680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.
    Wolin EM
    Oncologist; 2015 Oct; 20(10):1123-31. PubMed ID: 26306904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.